Summit Therapeutics Plc Stock Buy Hold or Sell Recommendation
| SMMT Stock | USD 20.79 1.60 8.34% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Summit Therapeutics PLC is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Summit Therapeutics PLC given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Summit Therapeutics PLC, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Summit Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Summit and provide practical buy, sell, or hold advice based on investors' constraints. Summit Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Summit |
Execute Summit Therapeutics Buy or Sell Advice
The Summit recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Summit Therapeutics PLC. Macroaxis does not own or have any residual interests in Summit Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Summit Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Summit Therapeutics Trading Alerts and Improvement Suggestions
| Summit Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Summit Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from fool.com: This Could Be the Catalyst That Sends Summit Therapeutics Stock Higher This Year |
Summit Therapeutics Returns Distribution Density
The distribution of Summit Therapeutics' historical returns is an attempt to chart the uncertainty of Summit Therapeutics' future price movements. The chart of the probability distribution of Summit Therapeutics daily returns describes the distribution of returns around its average expected value. We use Summit Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Summit Therapeutics returns is essential to provide solid investment advice for Summit Therapeutics.
| Mean Return | 0.32 | Value At Risk | -7.91 | Potential Upside | 9.31 | Standard Deviation | 5.48 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Summit Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Summit Stock Institutional Investors
The Summit Therapeutics' institutional investors refer to entities that pool money to purchase Summit Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Ubs Group Ag | 2024-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 910 K | Northern Trust Corp | 2024-12-31 | 871.4 K | Candriam Luxembourg S.c.a. | 2024-12-31 | 842.6 K | Td Asset Management Inc | 2024-12-31 | 838 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 561 K | Twin Tree Management, Lp | 2024-12-31 | 495.8 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 493.2 K | Baker Bros Advisors Lp | 2024-12-31 | 24.4 M | Vanguard Group Inc | 2024-12-31 | 11.7 M |
Summit Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 2.6M | 5.4M | 576.8M | (577.2M) | 33.8M | 35.5M | |
| Free Cash Flow | (48.5M) | (72.9M) | (42.2M) | (76.9M) | (142.2M) | (135.1M) | |
| Depreciation | 2.0M | 2.5M | 2.5M | 2.1M | 89K | 84.6K | |
| Other Non Cash Items | (385K) | 497K | 14.1M | 524.4M | 12.7M | 12.0M | |
| Capital Expenditures | 421K | 306K | 624K | 128K | 139K | 132.1K | |
| Net Income | (52.7M) | (88.6M) | (78.8M) | (614.9M) | (221.3M) | (210.2M) | |
| End Period Cash Flow | 66.4M | 71.8M | 648.6M | 71.4M | 105.2M | 62.8M | |
| Change To Netincome | 4.5M | 4.6M | 13.6M | 26.1M | 30.0M | 31.5M |
Summit Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Summit Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Summit Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Summit stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | 2.58 | |
σ | Overall volatility | 5.63 | |
Ir | Information ratio | 0.08 |
Summit Therapeutics Volatility Alert
Summit Therapeutics PLC exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Summit Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Summit Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Summit Therapeutics Implied Volatility
Summit Therapeutics' implied volatility exposes the market's sentiment of Summit Therapeutics PLC stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Summit Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Summit Therapeutics stock will not fluctuate a lot when Summit Therapeutics' options are near their expiration.
Summit Therapeutics Fundamentals Vs Peers
Comparing Summit Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Summit Therapeutics' direct or indirect competition across all of the common fundamentals between Summit Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Summit Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Summit Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Summit Therapeutics to competition |
| Fundamentals | Summit Therapeutics | Peer Average |
| Return On Equity | -0.95 | -0.31 |
| Return On Asset | -0.41 | -0.14 |
| Current Valuation | 14.93 B | 16.62 B |
| Shares Outstanding | 737.68 M | 571.82 M |
| Shares Owned By Insiders | 84.36 % | 10.09 % |
| Shares Owned By Institutions | 12.91 % | 39.21 % |
| Number Of Shares Shorted | 21.45 M | 4.71 M |
| Price To Earning | 2.85 X | 28.72 X |
| Price To Book | 39.45 X | 9.51 X |
| Price To Sales | 753.90 X | 11.42 X |
| Gross Profit | 705 K | 27.38 B |
| EBITDA | 313 K | 3.9 B |
| Net Income | (221.31 M) | 570.98 M |
| Cash And Equivalents | 121.97 M | 2.7 B |
| Cash Per Share | 0.61 X | 5.01 X |
| Total Debt | 7.22 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 8.22 X | 2.16 X |
| Book Value Per Share | 0.53 X | 1.93 K |
| Cash Flow From Operations | (142.11 M) | 971.22 M |
| Short Ratio | 9.05 X | 4.00 X |
| Earnings Per Share | (0.31) X | 3.12 X |
| Target Price | 34.69 | |
| Number Of Employees | 159 | 18.84 K |
| Beta | -1.04 | -0.15 |
| Market Capitalization | 15.34 B | 19.03 B |
| Total Asset | 435.56 M | 29.47 B |
| Retained Earnings | (1.21 B) | 9.33 B |
| Working Capital | 382.02 M | 1.48 B |
| Current Asset | 20.86 M | 9.34 B |
| Current Liabilities | 3.21 M | 7.9 B |
| Net Asset | 435.56 M |
Note: Acquisition by Xia Yu of 5438 shares of Summit Therapeutics at 18.35 subject to Rule 16b-3 [view details]
Summit Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Summit . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Summit Therapeutics Buy or Sell Advice
When is the right time to buy or sell Summit Therapeutics PLC? Buying financial instruments such as Summit Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2024 | 2025 (projected) | Working Capital | 47.0M | 49.3M | Market Cap | 12.8B | 13.5B |
Use Investing Ideas to Build Portfolios
In addition to having Summit Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.